University of Minnesota

Mayo Foundation for Medical Education and Research

Wayne State University

Jayanth Panyam

Daniel A Vallera

John R Ohlfest

Stephen Kalscheuer

Suresh Kumar Swaminathan

Thomas R Hoye

Christopher Ward Macosko

Alan P Hudson

Judith A Whittum-Hudson

Tanmoy Sadhukha

Wayne T Nicholson

Adam Wohl

Nathan J Smischney

Ameya Kirtane

Vidhi D Khanna

The present invention relates to diagnostic and therapeutic agents comprising recombinant antibody fragments to bind a protein associated with cancer and methods of use of these diagnostic and therapeutic agents.

Antibody fragments for detecting cancer and methods of use

Pharmaceutical formulations comprising ketamine, propofol, and a lipid are provided. Methods of making the formulations and methods of using the formulations to provide sedation, amnesia, analgesia, anxiolysis, and/or stable hemodynamics are also provided.

Ketamine and propofol admixture

Certain embodiments of the present invention provide functionalized nanoparticles and methods of use thereof. Certain embodiments provide nanoparticles functionalized with streptokinase. Certain embodiments of the present invention provide methods for treating a pathological fibrin associated disorder (e.g., cancer) in an animal.

Functionalized nanoparticles and methods of use thereof

Disclosed herein are a monoclonal antibody that specifically binds to human CD133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Single-chain variable fragment anti-CD133 antibodies and uses thereof

The invention provides silicate prodrugs comprising a therapeutic agent linked to one or more groups of formula (I): &#x2014;Si(OR)(I); wherein each R independently has any of the values defined herein, as well as nanoparticles comprising such compounds.

Taxane silicate prodrugs and nanoparticles

Disclosed herein are a monoclonal antibody that specifically binds to human CD 133 and single-chain variable fragments thereof. Also disclosed herein is a hybridoma that produces the monoclonal antibody that specifically binds to human CD133.

Single chain variable fragment anti-CD133 antibodies and uses thereof

Compositions of nanoparticles and targeting moieties for imaging and treating Chlamydial infection are provided, including nanoparticles conjugated to folic acid and comprising at least one antibiotic effective against

Growing community of inventors

Plymouth, MN, United States of America

Jayanth Panyam